Last week saw a large number of broker notes hitting the wires once again. Three buy ratings that caught my eye are summarised below.
Here's why brokers think investors ought to buy them next week:
BWP Trust (ASX: BWP)
According to a note out of Ord Minnett, its analysts have upgraded this real estate investment trust's shares to a buy rating with an improved price target of $4.40. The broker believes that BWP, which is predominantly a landlord to Bunnings Warehouse, is undervalued. Especially given its long leases. I agree with Ord Minnett on BWP and believe it is a great option for investors. This is particularly the case for income investors due to its attractive yield.
CSL Limited (ASX: CSL)
Analysts at Citi have retained their buy rating and $334.00 price target on this biotherapeutics company's shares. The broker appears pleased with its decision to exercise its right to acquire Vitaeris and sees potential in its clazakizumab product. Outside this, the broker believes that increasing demand for flu vaccines could offset some of the potential weakness in plasma collections in FY 2021. I agree with Citi and would be a buyer of CSL's shares.
Qantas Airways Limited (ASX: QAN)
A note out of UBS reveals that its analysts have retained their buy rating and lifted their price target on this airline operator's shares to $5.50. According to the note, the broker believes there is a lot of pent up demand for travel and expects the domestic travel market to rebound strongly when border restrictions are lifted. This has led to the broker upgrading its earnings forecasts and lifting its price target accordingly. As long as there isn't a second wave, I think Qantas could prove to be a good investment.
